(Dallas, TX. – September 19, 2011) StockGuru Shines its Spotlight on CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products, using its patented technologies, for use in healthcare and security markets. The Company reported financial results for the third quarter ended July 31, 2011, on Friday. The Company closed on September 19, 2011, at $0.035, trading in a fifty-two week range of $0.09 – 0.015.
“We continue to make strides toward launching our Valimed G4 Medication Validation system and expect to reach full commercialization over the next 60 days. Our target pipeline of hospitals and healthcare agencies continues to build as our marketing efforts drive interest nationwide. We are confident we will begin placing units over the remainder of this year, while building momentum to expand market penetration in 2012. We have been invited to present at several industry events over the next two quarters which should generate significant leads to expand our pipeline and position us for growth as we enter the 2012 calendar year,” stated Jeff Brumfield, chairman and chief executive officer of CDEX. “Although our security division has not accelerated sales as expected, we believe CDEX is ideally situated to support increased demand for our ID2 product line when municipal and state government budgets recover over the next 12 months. Overall we are very pleased with our progress as a company, we continue to monitor or costs as evidenced by our significant reduction in spending and debt, while generating positive cash flow from operations. We believe our continued progress towards the launch of the Valimed G4 and increasing market interest in the ID2 product line positions CDEX for significant growth as we push towards 2012.”
Third Quarter 2011 Financial Results
- Total revenues for the third quarter ended July 31, 2011 were approximately $232,000, a 15% increase compared to $202,000 for the third quarter of 2010. The $30,000 increase was primarily attributable to the increase in the sales of ID2 Meth Scanner.
- Total operating expenses for the quarter ended July 31, 2011 were approximately $240,000, a 55% decrease compared with $533,000 for the same period 2010. The $293,000 decrease was primarily attributable to decreases in consulting, professional and legal expenses, travel, marketing and general operating expenses partially offset by increases in non-cash share-based expenses, research and development, employee compensation. The increase in research and development is primarily based on the increased focus on the further advancement of the Pocket ID2 detection device and Valimed G4 Medication Validation system.
- Net loss for the quarter ended July 31, 2011 was approximately $258,000, or $(0.00) per share, based on 95,291,618 basic weighted common shares outstanding compared with a net loss of $537,000, or $(0.01) per share based on 65,239,634 basic weighted common shares outstanding, for the same period in 2010.
- The Company’s cash position increased to approximately $130,000 for the period ending July 31, 2011 compared with $117,000 for the previous quarter ended April 30, 2011. At July 31, 2011, the Company had $524,000 in total assets compared to $491,000 from the previous quarter ended April 30, 2011. Total liabilities were reduced by $1.1 million to $2.7 million for the period ending July 31, 2011 compared with $3.8 million the previous quarter end April 30, 2011 and reduced by $1.4 million from $4.1 million for yearend October 31, 2010.
- The company generated positive cash flow from operation of $37,000 for the quarter ended July 31, 2011 vs negative cash flow of $68,000 for the same period the previous year.
Recent Developments
- Announced the Sale and Shipment of Ten ID2 Meth Scanners: The Company sold and shipped 10 units of the ID2 Meth Scanners to the Northeastern Colorado Association of Governments and Healing Tree Addiction Treatment Solutions, Inc. The order represented the largest direct sale and shipment of ID2 Meth Scanners by CDEX to date.
- CDEX Presented the Pocket ID2 at the 2011 NHTSA Bi-Regional Law Enforcement Training Summit: Company representatives presented the Pocket ID2™ device at the 2011 NHTSA Bi-Regional Law Enforcement Training Summit. The training summit, which took place June 21-23, 2011 in Louisville, KY, brought together law enforcement divisions from the Southeast, Mid-Atlantic and Mid-West regions of the US.
- Company tapped Public Safety Industry Veteran as Director of Outside Sales: Public safety industry veteran John McConnell joined the CDEX team as Director of Outside Sales. Mr. McConnell’s professional background spans more than 20 years as an advisor and senior executive with several leading security and technology companies.
About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com.
Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as “expects,” “plans,” “may,” “believes,” “should,” “intends,” and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.
To view this StockGuru Spotlight, please visit: http://stockguru.com/category/latest-spotlights/
To get free alerts on this and other similar stocks, please register here:
What is the StockGuru Spotlight?
Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.
StockGuru looks for potential break-out candidates in The StockGuru Spotlight. Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage. There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below. StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.
To feature a company in The StockGuru Spotlight please contact the Publisher at [email protected]. If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile. Please contact the StockGuru Publisher John Pentony at this email address: [email protected].
Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage. When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present. Additionally SG also discloses any anticipated compensation in the future. Compensation is typically in cash. Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
John Pentony, Publisher, Stockguru.com
Tel: +1 469 252 3031
e-mail: [email protected]